4Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 expressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [
5Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplication[J]. J Clin Oncol, 2001,19(10) :2587.
6Baselga J, Tripathy D, Mendetsohn J, et al. Phase Ⅱ study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer[J]. J Clin Oncol, 1996,14(3) :737.
7Baselga J, Norton L, Albanell J, et al. Recombinant humanized antiHER2 antibody(Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts[J]. Cancer Res, 1998,58 (13): 2825.
8Kunisue H, Kurebayashi J ,Otsuki T, et al. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both eestrogen receptors and HER2[J]. Br J Cancer, 2000,82(1):46.
9Pegram MD, Lipton A, Hayes DF, et al. Phase Ⅱ study of receptorenhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monolnal antibody plus cisplatin in patients with HER2/neu-over-erpressing metastatic breast cancer refractory to chemo
10Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab[J]. Nature,2003,421 (6924) :756.
8LE JEUNNE C, BILLON N, DANDON A, et al. Off-label prescriptions:how to identify them, frame them, announce them and monitor them in practice? [ J] .Therapie, 2013, 68(4) :225-239.
9OU S H,SOO R A, KUBO A, et al.Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-Rearranged (ROSI-, RET-,AXL-, PDGFR-~~-, NTRK1-) non-small cell lung cancer globally? [J] .Front Oncol, 2014,4: 58. doi: 10.3389/fonc. 2014.00058.
10PAK IN D M, BRAY F, FERLAY J, et al. Estimating the world cancer burden: Globocan 2000 [J]. Int J Cancer, 2001,94(2) : 153-156.
